U.S. Markets close in 1 hr 10 mins

Altimmune to acquire California company for up to $93M

Sara Gilgore
Altimmune to acquire California company for up to $93M

The deal puts Spitfire’s flagship product candidate — a treatment for nonalcoholic steatohepatitis, or NASH — into Altimmune’s pipeline of flu and anthrax vaccines.